Group 1 - The company and its subsidiaries will conduct related transactions based on principles of honesty, fairness, and market pricing, ensuring the fairness of these transactions [1][9] - The company plans to purchase raw materials from Langhui Petrochemical, which is a major supplier of plasticizers and resin, providing advantages in cost and supply stability [1][2] - The independent directors have approved the related transactions for 2026, confirming that these will not affect the company's independence or financial status [3][4] Group 2 - The company has signed a 13-year lease agreement for office space and parking with Zibo Henghui, with a rental fee of 600,000 RMB per year for the first five years, and market-based adjustments thereafter [5][10] - The company intends to continue leasing the property at the same rate after the initial five-year period, ensuring operational convenience and cost-effectiveness [11][12] - The total amount of related transactions with the mentioned parties has reached approximately 627.87 million RMB as of the announcement date [13] Group 3 - The company plans to apply for a total credit limit of up to 3 billion RMB for 2026, which includes various financial instruments to support its operations [18][19] - The company will provide guarantees for subsidiaries based on their financial health, with a maximum of 2 billion RMB for those with a debt ratio above 70% [19][25] - The company has no overdue guarantees or legal issues related to its guarantees as of the announcement date [26] Group 4 - The company intends to invest up to 1.1 billion RMB in high-security, liquid financial products to enhance fund utilization and returns [30][31] - The investment will be made using idle funds, ensuring that normal operations are not affected [38] - The company has established risk control measures for these investments, including regular audits and strict selection of investment targets [37][54] Group 5 - The company plans to engage in financial derivatives trading to hedge against currency and interest rate risks, with a maximum margin and contract value set for 2026 [41][44] - The trading will be conducted with qualified financial institutions, ensuring compliance with regulations [46][49] - The company has outlined risk management strategies to mitigate potential market, liquidity, and operational risks associated with these transactions [50][54] Group 6 - The company has approved a budget of up to 5 million RMB for charitable donations in 2026, reflecting its commitment to social responsibility [59][60] - The donations will be funded from the company's own resources and will not adversely impact its operations [61] Group 7 - The company has proposed to purchase liability insurance for its directors and senior management to enhance risk management [63][64] - The insurance coverage will have a limit of up to 100 million RMB, with an annual premium not exceeding 400,000 RMB [64]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002314 证券简称：南山控股 公告编号：2025-055 深圳市新南山控股（集团）股份有限公司 第七届董事会第二十五次会议决议公告 深圳市新南山控股（集团）股份有限公司（以下简称"公司"）第七届董事会第二十五次会议通知于2025 年12月8日以直接送达、邮件等方式发出，会议于2025年12月12日以通讯会议方式召开。 具体内容详见2025年12月13日刊登于《证券时报》《上海证券报》和巨潮资讯网的《关于向控股股东借 款暨关联交易的公告》，公告编号2025-057。 本次会议由董事长舒谦先生召集，会议应出席董事9名，实际出席董事9名。本次会议的召开符合有关法 律、法规及《公司章程》等的规定。经审议，会议形成如下决议： 1. 审议通过《关于聘请2025年度审计机构的议案》。 表决结果：9票同意，0票反对，0票弃权。 该议案已经公司第七届董事会审计委员会2025年第五次会议审议通过。具体内容详见2025年12月13日刊 登于《证券时报》《上海证券报》和巨潮资讯网的《关于聘请2025年度审计机构的公告》，公告编号 2025-056。 本议案需提交股东会审 ...

证券代码：600446 证券简称：金证股份 公告编号：2025-063 深圳市金证科技股份有限公司 关于关联交易的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 基于公司日常经营及业务发展需要，深圳市金证科技股份有限公司（以下简称"公司"）与参股公司港 融科技有限公司（以下简称"港融科技"）签订《业务合作框架协议》，参考市场价格及预计的工作量， 2026年1月1日至2026年12月31日预计公司向港融科技采购服务费用金额预计不超过6,000万元（人民币 元，以下同），港融科技向公司采购服务费用金额预计不超过2,800万元，定价原则上不高于同类业务 市场价格，实际结算金额以双方实际签署的业务合同为准。 ● 基于公司日常经营及业务发展需要，公司与参股公司深圳市钐烽科技有限公司（以下简称"钐烽科 技"）签订《业务合作框架协议》，参考市场价格及预计的工作量，2026年1月1日至2026年12月31日公 司向钐烽科技采购服务费用金额预计不超过3,000万元，钐烽科技向公司采购服务费用金额预计不超过 1,40 ...

Group 1 - The company plans to submit its 2026 annual routine related party transactions for shareholder meeting approval [2][4][52] - The related party transactions will be conducted based on principles of openness, fairness, and justice, ensuring no harm to minority shareholders and maintaining the company's independence [2][16] - The estimated amount for the 2026 routine related party transactions is 937 million yuan, with a floating upper limit of 10% [5][16] Group 2 - The company has signed a financial service agreement with Baowu Group Finance Co., Ltd., providing services such as credit and settlement [6][36] - The maximum credit limit with the financial company is set at 200 million yuan, with a daily deposit limit of 95 million yuan and a maximum loan balance of 5 million yuan [8][40] - The agreement is valid from January 1, 2026, to December 31, 2027 [41] Group 3 - The company has a long-standing relationship with Baowu Group and its subsidiaries, providing information technology and automation solutions [16][45] - The pricing for related party transactions adheres to the company's management system, ensuring compliance with government pricing or market rates [15][42] - The financial company operates under the supervision of national financial regulatory authorities, ensuring a controlled risk environment [45][46]

登录新浪财经APP 搜索【信披】查看更多考评等级 （来源：泰勒斯资本观察） 【特别提醒】：本文仅代表个人观点，作为个人研究立此存照，与志同道合者共勉，不代表买卖建议， 股市有风险，入市需谨慎。 2025年12月12日，人福医药（SH600079）发布《关于收到中国证券监督管理委员会湖北监管局 <行政 处罚事先告知书> 的公告》《关于实施其他风险警示暨 停牌的公告》，主要内容如下: 人福医药涉嫌违法的事实如下 2020年，人福医药与控股股东当代集团发生非经营性资金占用累计发生额25.02亿元，占最近一期经审 计净资产的17.58%。 2021年，人福医药与控股股东当代集团发生非经营性资金占用累计发生额81.79亿元，占最近一期经审 计净资产的62.97%。 2022年1月至3月，人福医药与控股股东当代集团发生非经营性资金占用累计发生额21.04 亿元，占最近 一期经审计净资产的13.44%。 （三）定期报告存在重大遗漏 人福医药在2020年年度报告中遗漏披露控股股东当代集团非经营性资金占用累计发生额25.02亿元，占 人福医药2020年年度报告记载的净资产的19.26%。 二、人福医药未及时披露关联交易，202 ...

证券日报网讯 12月12日晚间，漳州发展发布公告称，公司于2025年12月12日召开的第九届董事会独立 董事2025年第一次专门会议审议通过了《关于全资子公司漳州市水利电力工程有限公司与关联方签署关 联交易合同的议案》。公司全资子公司漳州市水利电力工程有限公司（简称"水利电力"）就漳州 2022P16地块（湖湾之尚）建设项目供电工程及漳州2023G01地块供配电工程拟与福建漳龙建投集团有 限公司（简称"漳龙建投"）签署《建设工程施工专业分包合同》，合同价款合计暂定为1，930万元。鉴 于漳龙建投为公司控股股东福建漳龙集团有限公司（以下简称漳龙集团）的下属企业，上述交易构成关 联交易。 （文章来源：证券日报） ...

Core Viewpoint - The announcement from Xinbang Pharmaceutical regarding its indictment for bribery marks a significant escalation in a long-standing corruption case involving key figures in the company and its subsidiary, Guizhou Keke Pharmaceutical [1][2]. Group 1: Company Overview - Xinbang Pharmaceutical has been implicated in a bribery case that has now escalated to judicial proceedings, indicating the severity of the issues at hand [1]. - The company’s reputation has suffered greatly, with its stock price dropping over 9% following the announcement, contrasting sharply with a previous surge [1]. Group 2: Key Individuals and Relationships - The case is linked to Wang Xiaolin, former Vice President and Director of the Affiliated Hospital of Guizhou Medical University, who played a pivotal role in the establishment of Guizhou Keke Pharmaceutical [2][12]. - Wang Xiaolin and Xinbang's actual controller, An Huailue, have been accused of colluding to embezzle funds during the restructuring of the company [3][4]. Group 3: Financial Implications - Guizhou Keke Pharmaceutical contributed over 35% of Xinbang Pharmaceutical's revenue and nearly 27% of its net profit in 2023, highlighting the company's dependency on this subsidiary [8]. - The acquisition of Guizhou Keke by Xinbang in 2014 was valued at approximately 997 million yuan, with a staggering premium of 340.60% over its book value, raising concerns about the legitimacy of the transaction [9]. Group 4: Historical Context and Corruption - The corruption scheme reportedly spans over two decades, with Wang Xiaolin's actions leading to significant financial misconduct within the healthcare supply chain [14]. - The merger and acquisition process was characterized by conflicts of interest, as Xinbang's revenue was heavily reliant on transactions with its subsidiary, raising red flags about the integrity of the deal [15]. Group 5: Future Outlook - With the bribery case now in judicial proceedings, the once lucrative subsidiary, Guizhou Keke, is now viewed as a potential liability for Xinbang Pharmaceutical [11].

根据本次转让资产一揽子交易方案，按照中联资产评估集团四川有限公司出具的《成都高投芯未半导体 有限公司拟转让设备类资产评估项目资产评估报告》（中联川评报字[2025]第146号），截至2025年9月 30日，本次标的资产账面价值17,361.92万元，评估值18,008.17万元（不含税），评估增值646.25万元， 增值率3.72%。经测算，本次标的资产转让含税价为20,349.23万元。同时，芯未公司将现有部分厂房出 租给高投集团用于标的资产运行，租赁期限自2026年1月1日起至2026年12月31日止，年度租金按照中联 资产评估集团四川有限公司出具的评估基准日为2025年9月30日的《成都高投芯未半导体有限公司拟出 租部分资产所涉及物业的市场租金评估项目资产评估报告》（中联川评报字[2025]第149号）评估价格 确定为522.75万元（含税价）。高投集团为公司控股股东，属于公司的关联方，本次交易构成关联交 易。本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 格隆汇12月12日丨高新发展(000628.SZ)公布，为支持公司科技转型培育的功率半导体业务发展，提高 下属功率半导体设计 ...

中航西飞公告称，公司预计2026年度与航空工业财务发生的金融业务额度为：日最高存款限额不超300 亿元，存款年利率0.15% - 3.02%；可循环贷款额度不超160亿元，贷款年利率2% - 2.72%；综合授信额 度不超250亿元。该交易构成关联交易，已获董事会通过，尚需股东会批准。截至2025年11月30日，公 司在航空工业财务存款余额66.53亿元，贷款余额1.40亿元，用信6.17亿元，利息收支相抵净收入1.05亿 元。 ...

证券日报网讯12月12日，凌霄泵业（002884）在互动平台回答投资者提问时表示，领恒是公司实际控制 人投资的公司。凌霄和领恒是两家完全独立的企业。凌霄泵业公司生产塑料卫浴泵、不锈钢泵、清水 泵、潜水泵、管道泵等产品，两家公司的产品不相同，有各自的管理团队和完善的管理制度、业务流 程，两家公司按照相应制度、流程能很好地运作。凌霄与领恒的关联交易价格按公平、公正、合理的原 则，参考市场价格确定，关联交易情况可查阅2024年年度报告及2025年半年度报告。 ...